Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Trintellix

Vortioxetine Hydrobromide

RLDNDA 204447 4 strengths Takeda Pharms USA
Approved
Sep 30, 2013
Strengths
4
Listed patents
20

What does the FDA Orange Book show for Trintellix?

Trintellix contains Vortioxetine Hydrobromide and is the new drug FDA Orange Book record for NDA 204447. The application has 4 presentations with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 204447

New drug application identity from the Orange Book snapshot.

Application holder
Takeda Pharmaceuticals USA Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
4

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription and Discontinued

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
20

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
2

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
001EQ 5MG BASETABLETORALPrescriptionNone posted
RLD
002EQ 10MG BASETABLETORALPrescriptionNone posted
RLD
003EQ 15MG BASETABLETORALDiscontinuedNone posted
RLD
004EQ 20MG BASETABLETORALPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Takeda Pharmaceuticals USA Inc

The Orange Book identifies this organization as the applicant responsible for NDA 204447.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

Status varies by presentation: 3 prescription and 1 on the Discontinued Drug Product List

Orange Book status is assigned at the product-presentation level, so one strength can remain listed as prescription or OTC while another appears on the discontinued list.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

19 listed patent expirations and 2 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Sep 21, 2032. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

0 other ANDAs and 0 other NDAs found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 204447 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Tablet · Oral

Vortioxetine Hydrobromide

1 application
Product rows
4
Active applications
1
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-204447

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

4 approved presentations · NDA 204447
RLD
Strength
EQ 5MG BASE
Dosage form
TABLET
Route
ORAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    13 yr ago

  2. Patent 7144884 expires

    Listed drug substance patent expiration.

    1 mo ago

  3. Today

  4. Exclusivity ends · M-232

    New use / labeling-change exclusivity (3 years)

    in 28 d

  5. Patent 7144884*PED expires

    Listed listed patent expiration.

    in 5 mo

  6. Exclusivity ends · PED

    Pediatric exclusivity (adds 6 months)

    in 7 mo

  7. Patent 11458134 expires

    Listed drug product patent expiration.

    in 11 mo

  8. Patent 8969355 expires

    Listed method-of-use patent (U-1668) expiration.

    in 11 mo

  9. Patent 9125908 expires

    Listed method-of-use patent (U-2309) expiration.

    in 11 mo

  10. Patent 9125909 expires

    Listed method-of-use patent (U-2309) expiration.

    in 11 mo

  11. Patent 9125910 expires

    Listed method-of-use patent (U-2309) expiration.

    in 11 mo

  12. Patent 9227946 expires

    Listed method-of-use patent (U-1668) expiration.

    in 11 mo

  13. Patent 9861630 expires

    Listed method-of-use patent (U-1668) expiration.

    in 11 mo

  14. Patent 11458134*PED expires

    Listed listed patent expiration.

    in 1 yr 5 mo

  15. Patent 8969355*PED expires

    Listed listed patent expiration.

    in 1 yr 5 mo

  16. Patent 9125908*PED expires

    Listed listed patent expiration.

    in 1 yr 5 mo

  17. Patent 9125909*PED expires

    Listed listed patent expiration.

    in 1 yr 5 mo

  18. Patent 9125910*PED expires

    Listed listed patent expiration.

    in 1 yr 5 mo

  19. Patent 9227946*PED expires

    Listed listed patent expiration.

    in 1 yr 5 mo

  20. Patent 9861630*PED expires

    Listed listed patent expiration.

    in 1 yr 5 mo

  21. Patent 8722684 expires

    Listed drug substance patent expiration.

    in 5 yr

  22. Patent 8722684*PED expires

    Listed listed patent expiration.

    in 5 yr 6 mo

  23. Patent 9278096 expires

    Listed method-of-use patent (U-2436) expiration.

    in 5 yr 9 mo

  24. Patent 9278096*PED expires

    Listed listed patent expiration.

    in 6 yr 3 mo

Patent & exclusivity timeline

Protection horizon
20262027202820292030203120322033TodayPatent 7144884: 2026-06-17Patent 7144884Exclusivity M-232: 2026-08-23Exclusivity M-232Patent 7144884*PED: 2026-12-17Patent 7144884*PEDExclusivity PED: 2027-02-23Exclusivity PEDPatent 11458134: 2027-06-15Patent 11458134Patent 8969355: 2027-06-15Patent 8969355Patent 9125908: 2027-06-15Patent 9125908Patent 9125909: 2027-06-15Patent 9125909Patent 9125910: 2027-06-15Patent 9125910Patent 9227946: 2027-06-15Patent 9227946Patent 9861630: 2027-06-15Patent 9861630Patent 11458134*PED: 2027-12-15Patent 11458134*PEDPatent 8969355*PED: 2027-12-15Patent 8969355*PEDPatent 9125908*PED: 2027-12-15Patent 9125908*PEDPatent 9125909*PED: 2027-12-15Patent 9125909*PEDPatent 9125910*PED: 2027-12-15Patent 9125910*PEDPatent 9227946*PED: 2027-12-15Patent 9227946*PEDPatent 9861630*PED: 2027-12-15Patent 9861630*PEDPatent 8722684: 2031-06-30Patent 8722684Patent 8722684*PED: 2031-12-30Patent 8722684*PEDPatent 9278096: 2032-03-21Patent 9278096Patent 9278096*PED: 2032-09-21Patent 9278096*PED
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

VORTIOXETINE HYDROBROMIDE

Strength

EQ 5MG BASE

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 204447

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Marketing exclusivity

Hatch-Waxman
  • M-232New use / labeling-change exclusivity (3 years)

    in 28 d

  • PEDPediatric exclusivity (adds 6 months)

    in 7 mo

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
71448841 mo ago
SubstanceProductU-1439
7144884*PEDin 5 mo
11458134in 11 mo
ProductU-3463
8969355in 11 mo
U-1668
9125908in 11 mo
U-2309
9125909in 11 mo
U-2309
9125910in 11 mo
U-2309
9227946in 11 mo
U-1668
9861630in 11 mo
U-1668
11458134*PEDin 1 yr 5 mo
8969355*PEDin 1 yr 5 mo
9125908*PEDin 1 yr 5 mo
9125909*PEDin 1 yr 5 mo
9125910*PEDin 1 yr 5 mo
9227946*PEDin 1 yr 5 mo
9861630*PEDin 1 yr 5 mo
8722684in 5 yr
SubstanceProduct
8722684*PEDin 5 yr 6 mo
9278096in 5 yr 9 mo
U-2436
9278096*PEDin 6 yr 3 mo

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

No other applications share this active ingredient.

View full Vortioxetine Hydrobromide family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Trintellix: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 204447 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo